Metformin--mode of action and clinical implications for diabetes and cancer.
Level 5 - mechanism / opinion, no new human data
Narrative review and mechanism-based reasoning with no primary empirical data.
PubMed 24393785 · doi:10.1038/nrendo.2013.256
What was done
This narrative review summarizes molecular and cellular mechanisms of metformin, focusing on alterations in cellular energy metabolism, inhibition of hepatic gluconeogenesis, glucagon signaling antagonism, mitochondrial complex I inhibition, AMPK stimulation, and potential anti-tumor pathways.
What was found
The abstract reports no numerical data. Qualitatively, it reports that metformin lowers glucose by inhibiting hepatic gluconeogenesis and opposing glucagon, driven by mitochondrial complex I inhibition that impairs cAMP and protein kinase A signaling. AMPK stimulation confers insulin sensitivity by modulating lipid metabolism rather than driving primary glucose lowering. Metformin is also noted to potentially influence tumorigenesis through systemic insulin reduction and direct induction of energetic stress.
Why it matters
It outlines how cellular energy disruption by metformin links its established role in glycemic control to potential therapeutic applications in oncology.
Limits
The paper is a narrative review presenting mechanistic theory rather than primary empirical clinical trial data. No quantitative effect sizes or systematic review methodologies are reported in the abstract.
Cited by
- supports The diabetes drug metformin acts to stimulate AMP kinase.